Logo

COO

The Cooper Companies, Inc.

COO

The Cooper Companies, Inc. • NASDAQ
$77.93 ▼ -0.01% (-0.01)
Market Cap $15.55 B
52w High $106.63
52w Low $61.78
Dividend Yield 0%
P/E 38.2
Volume 1.40M
Outstanding Shares 199.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.06B ▲ $516.3M ▲ $98.3M ▲ 9.271% ▲ $0.49 ▲ $272.7M ▲
Q2-2025 $1.002B ▲ $494.3M ▲ $87.7M ▼ 8.75% ▼ $0.439 ▼ $261.3M ▼
Q1-2025 $964.7M ▼ $478.2M ▼ $104.3M ▼ 10.812% ▼ $0.52 ▼ $270.3M ▼
Q4-2024 $1.018B ▲ $479.3M ▲ $117.5M ▲ 11.538% ▲ $0.59 ▲ $286.6M ▲
Q3-2024 $1.003B $470.5M $104.7M 10.441% $0.53 $281.2M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $124.9M ▲ $12.377B ▼ $4.024B ▼ $8.353B ▲
Q2-2025 $116.2M ▲ $12.414B ▲ $4.125B ▲ $8.288B ▲
Q1-2025 $100.9M ▼ $12.222B ▼ $4.095B ▼ $8.127B ▲
Q4-2024 $107.6M ▼ $12.315B ▲ $4.232B ▲ $8.083B ▲
Q3-2024 $109.7M $12.108B $4.183B $7.925B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $98.3M ▲ $261.4M ▲ $-98.1M ▼ $-156.3M ▼ $8.7M ▼ $164.5M ▲
Q2-2025 $87.7M ▼ $96.2M ▼ $-79.2M ▲ $-8.6M ▲ $15.2M ▲ $18.1M ▼
Q1-2025 $104.3M ▼ $190.6M ▼ $-96.8M ▲ $-96.6M ▼ $-6.7M ▼ $101.2M ▼
Q4-2024 $117.5M ▲ $268.1M ▲ $-241.6M ▼ $-28.4M ▲ $-2.1M ▲ $128.1M ▲
Q3-2024 $104.7M $207.5M $-124.1M $-87.6M $-2.8M $118.5M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Coopersurgical Segment
Coopersurgical Segment
 $340.00M ▲$320.00M ▼$330.00M ▲$340.00M ▲
Coopervision Segment
Coopervision Segment
 $680.00M ▲$650.00M ▼$670.00M ▲$720.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past several years, and profit before interest and taxes has grown alongside it, which points to a stable core business with improving scale. Gross profitability remains strong, suggesting the company still has good pricing power and cost control in its key product lines. Net income, however, has been choppy, with one unusually high year followed by more normal, lower profit levels, likely reflecting one‑off items or accounting adjustments rather than a permanent shift. Overall, the trend shows a healthy, expanding business but with earnings that can be noisy from year to year beneath the surface.

Balance Sheet

Balance Sheet The balance sheet shows a company that has grown in size while steadily adding to its equity base, which is a sign of accumulated retained earnings and ongoing reinvestment. Debt has risen compared with earlier years but has recently leveled off, leaving the company with a meaningful but seemingly manageable level of leverage. Cash on hand is relatively modest compared with total assets, which increases the importance of reliable cash generation and access to credit markets. Taken together, the financial position looks solid but not overly conservative, with some dependence on continued business stability to comfortably support the current debt load.

Cash Flow

Cash Flow Cash generated from the business has been consistently positive and reasonably stable, supporting the view that underlying operations are sound and recurring. Free cash flow has also been positive each year, though it has moved up and down as the company has stepped up spending on new facilities, equipment, or technology. Rising capital investment suggests a focus on growth and upgrading capabilities, but it temporarily weighs on near‑term free cash flow. Overall, the cash profile looks dependable, with enough internal funding to support both day‑to‑day needs and ongoing investment, as long as operating trends remain favorable.

Competitive Edge

Competitive Edge The company holds a strong position in two specialized healthcare niches: contact lenses and women’s health and fertility solutions. In contact lenses, it benefits from advanced materials, designs tailored to specific eye conditions, and a strong presence in fast‑growing areas like daily disposables and myopia management for children. In women’s health, it offers a broad portfolio that runs across contraception, fertility, and surgical tools, which makes it a key partner for clinics and physicians. Patented technologies, deep relationships with specialists, and a broad global footprint create meaningful barriers for new entrants and help defend market share against larger diversified medical device players.

Innovation and R&D

Innovation and R&D Innovation is a central part of the strategy, with clear emphasis on proprietary materials, smart lens designs, and AI‑enabled reproductive genetics. In vision care, unique technologies focused on comfort, dryness, digital eye strain, and especially myopia control set its products apart and position the firm in segments expected to grow faster than the overall market. In women’s health, the company combines differentiated devices like the copper IUD and office‑based visualization systems with advanced genetic testing tools that use machine learning to support better IVF outcomes. Ongoing R&D and targeted acquisitions are expanding these platforms, suggesting a robust pipeline rather than reliance on a few legacy products.

Summary

Overall, The Cooper Companies appears to be a steadily growing medical device business with strong positions in focused niches and a clear innovation engine behind it. Revenue and operating profits show healthy upward momentum, backed by a solid, if moderately leveraged, balance sheet and reliable cash generation. The main financial watchpoints are the volatility in reported net income and the relatively low cash cushion, which make consistent execution important. Strategically, the company benefits from specialized technologies, protected intellectual property, and exposure to structural trends like myopia management and fertility treatments, all of which provide both opportunities for continued growth and a need for sustained investment and careful risk management.

NEWS

November 19, 2025 · 8:45 AM UTC

Browning West Delivers Letter to The Cooper Companies Board of Directors

Read more

November 4, 2025 · 4:15 PM UTC

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025

Read more

September 17, 2025 · 4:15 PM UTC

CooperCompanies Announces Expanded Share Repurchase Program

Read more